Market Cap 67.13M
Revenue (ttm) 58.44M
Net Income (ttm) -34.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -58.66%
Debt to Equity Ratio 0.00
Volume 84,000
Avg Vol 128,612
Day's Range N/A - N/A
Shares Out 12.10M
Stochastic %K 2%
Beta 0.99
Analysts Strong Sell
Price Target $8.50

Company Profile

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, de...

Industry: Medical Devices
Sector: Healthcare
Phone: 888 536 7271
Address:
2800 Discovery Drive, Orlando, United States
ap20
ap20 Apr. 14 at 5:07 PM
$LNSR Easy double from here..
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 11 at 1:41 PM
$LNSR Mixed signals here — and the market usually punishes that. 👉Click to view @NasdaqPulse for timely updates amid the volatility. On one hand, procedure volume is ripping: +21% YoY and now holding >23% U.S. share. That’s real demand, real usage, real traction. But here’s the catch… system sales are lagging HARD. Management is pointing fingers at international distributors, saying merger uncertainty is slowing adoption. Maybe… but that feels like a convenient excuse. If the tech is truly gaining traction, system demand should FOLLOW procedure growth — not stall out. This divergence matters: → Strong usage but weak hardware sales = potential growth ceiling → Street starts questioning scalability → Narrative risk increases FAST Right now this is a “trust vs verify” setup. If system sales don’t catch up soon, this could flip from growth story → broken story real quick.
1 · Reply
JordiWild
JordiWild Apr. 11 at 10:30 AM
$LNSR lets gooo 6-7$🚀
0 · Reply
JordiWild
JordiWild Apr. 11 at 10:29 AM
$LNSR 6-7$
0 · Reply
SwingTraderPro1
SwingTraderPro1 Apr. 10 at 7:57 PM
For $LNSR, procedure volume has been doing well, with a >21% jump y/y, now up to >23% share in the U.S. The problem is with system sales, which are lacking. Management blames international distributors for being hesitant because of the merger. Not sure I buy that.
0 · Reply
TradeMechanics_
TradeMechanics_ Mar. 31 at 2:33 PM
Today’s move in $LNSR feels like a mix of beta tailwinds and a hint of alpha starting to show. What stood out? Recurring revenue. That’s the piece the market actually rewards over time — more predictable, more defensible, more scalable. That’s a quiet but important signal. The bigger question: why couldn’t the machines keep building on that earlier momentum? Lantern Pharma is at a point where execution matters more than narrative. If management can reignite growth and operational consistency over the next few quarters, this could shift from “watchlist” to “story re-rating.” For now, it’s not about one day’s price action — it’s about whether this becomes sustained traction or just another chop phase.
0 · Reply
ap20
ap20 Mar. 31 at 11:47 AM
$LNSR Second best sales revenue ever. Highest procedure volume ever. Things are still moving. Was $16 on 4q earnings day last year.. Risk reward at $6 pretty dang good. Long.
0 · Reply
DonCorleone77
DonCorleone77 Mar. 31 at 10:35 AM
$LNSR Lensar reports Q4 EPS (12c) vs. ($1.61) last year Reports Q4 revenue $16.03M vs. $16.73M last year. "While the recent transaction-related news was unexpected, we have quickly pivoted and are moving forward independently with a renewed commitment to advancing robotic laser cataract surgery through our industry-leading ALLY Robotic Laser Cataract System. Our objective is not only to expand our share of the laser-assisted cataract surgery market, but to expand the robotic laser cataract market itself, and continue to demonstrate we are well equipped to do so," said CEO Nick Curtis. "We closed 2025 with continued momentum in ALLY adoption and utilization, reinforcing the durability of our recurring revenue model, with 79% of revenue for both the fourth quarter and the full year coming from recurring sources. During Q4, we expanded the ALLY installed base to approximately 200 systems, representing a 48% increase over the end of 2024, while worldwide volume increased 22% in 2025 compared to 2024. Procedure growth, both in the U.S. and abroad, remained robust and reflects increasing utilization across our growing installed base, providing clear evidence of the compelling value surgeons see in our technology and a clear path for LENSAR to continue growing its recurring revenue base and its overall business."
0 · Reply
HotBaht
HotBaht Mar. 22 at 3:57 PM
$LNSR @SQUEAKSBANDIT You may be right but we have Q4 earnings at the end of the month and it's historically their best quarter. This will be the first earnings call in the last year and I expect we will hear good things about the speed of system placement in 2026 and beyond as they re-commit with dealers and refocus. The $10M was sorely needed but it definitely didn't cover the cost of this long regulatory scrutiny even without considering the associated slowdown in growth. They were negligent not requiring a larger reverse breakup fee. $15M-$30M would have been more typical given the deal size.
2 · Reply
ap20
ap20 Mar. 18 at 7:21 PM
$LNSR Added.
0 · Reply
Latest News on LNSR
LENSAR® Provides Update on Pending Acquisition by Alcon

Feb 25, 2026, 5:00 PM EST - 7 weeks ago

LENSAR® Provides Update on Pending Acquisition by Alcon


LENSAR to Participate in Two Upcoming Investor Conferences

Sep 4, 2024, 8:00 AM EDT - 1 year ago

LENSAR to Participate in Two Upcoming Investor Conferences


LENSAR to Present at Two Upcoming Investor Conferences

Nov 22, 2022, 8:00 AM EST - 3 years ago

LENSAR to Present at Two Upcoming Investor Conferences


Why Lensar Shares Are Trading Higher Today

Jun 13, 2022, 9:14 AM EDT - 4 years ago

Why Lensar Shares Are Trading Higher Today


ap20
ap20 Apr. 14 at 5:07 PM
$LNSR Easy double from here..
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 11 at 1:41 PM
$LNSR Mixed signals here — and the market usually punishes that. 👉Click to view @NasdaqPulse for timely updates amid the volatility. On one hand, procedure volume is ripping: +21% YoY and now holding >23% U.S. share. That’s real demand, real usage, real traction. But here’s the catch… system sales are lagging HARD. Management is pointing fingers at international distributors, saying merger uncertainty is slowing adoption. Maybe… but that feels like a convenient excuse. If the tech is truly gaining traction, system demand should FOLLOW procedure growth — not stall out. This divergence matters: → Strong usage but weak hardware sales = potential growth ceiling → Street starts questioning scalability → Narrative risk increases FAST Right now this is a “trust vs verify” setup. If system sales don’t catch up soon, this could flip from growth story → broken story real quick.
1 · Reply
JordiWild
JordiWild Apr. 11 at 10:30 AM
$LNSR lets gooo 6-7$🚀
0 · Reply
JordiWild
JordiWild Apr. 11 at 10:29 AM
$LNSR 6-7$
0 · Reply
SwingTraderPro1
SwingTraderPro1 Apr. 10 at 7:57 PM
For $LNSR, procedure volume has been doing well, with a >21% jump y/y, now up to >23% share in the U.S. The problem is with system sales, which are lacking. Management blames international distributors for being hesitant because of the merger. Not sure I buy that.
0 · Reply
TradeMechanics_
TradeMechanics_ Mar. 31 at 2:33 PM
Today’s move in $LNSR feels like a mix of beta tailwinds and a hint of alpha starting to show. What stood out? Recurring revenue. That’s the piece the market actually rewards over time — more predictable, more defensible, more scalable. That’s a quiet but important signal. The bigger question: why couldn’t the machines keep building on that earlier momentum? Lantern Pharma is at a point where execution matters more than narrative. If management can reignite growth and operational consistency over the next few quarters, this could shift from “watchlist” to “story re-rating.” For now, it’s not about one day’s price action — it’s about whether this becomes sustained traction or just another chop phase.
0 · Reply
ap20
ap20 Mar. 31 at 11:47 AM
$LNSR Second best sales revenue ever. Highest procedure volume ever. Things are still moving. Was $16 on 4q earnings day last year.. Risk reward at $6 pretty dang good. Long.
0 · Reply
DonCorleone77
DonCorleone77 Mar. 31 at 10:35 AM
$LNSR Lensar reports Q4 EPS (12c) vs. ($1.61) last year Reports Q4 revenue $16.03M vs. $16.73M last year. "While the recent transaction-related news was unexpected, we have quickly pivoted and are moving forward independently with a renewed commitment to advancing robotic laser cataract surgery through our industry-leading ALLY Robotic Laser Cataract System. Our objective is not only to expand our share of the laser-assisted cataract surgery market, but to expand the robotic laser cataract market itself, and continue to demonstrate we are well equipped to do so," said CEO Nick Curtis. "We closed 2025 with continued momentum in ALLY adoption and utilization, reinforcing the durability of our recurring revenue model, with 79% of revenue for both the fourth quarter and the full year coming from recurring sources. During Q4, we expanded the ALLY installed base to approximately 200 systems, representing a 48% increase over the end of 2024, while worldwide volume increased 22% in 2025 compared to 2024. Procedure growth, both in the U.S. and abroad, remained robust and reflects increasing utilization across our growing installed base, providing clear evidence of the compelling value surgeons see in our technology and a clear path for LENSAR to continue growing its recurring revenue base and its overall business."
0 · Reply
HotBaht
HotBaht Mar. 22 at 3:57 PM
$LNSR @SQUEAKSBANDIT You may be right but we have Q4 earnings at the end of the month and it's historically their best quarter. This will be the first earnings call in the last year and I expect we will hear good things about the speed of system placement in 2026 and beyond as they re-commit with dealers and refocus. The $10M was sorely needed but it definitely didn't cover the cost of this long regulatory scrutiny even without considering the associated slowdown in growth. They were negligent not requiring a larger reverse breakup fee. $15M-$30M would have been more typical given the deal size.
2 · Reply
ap20
ap20 Mar. 18 at 7:21 PM
$LNSR Added.
0 · Reply
FiftyEight
FiftyEight Mar. 18 at 1:01 PM
$EONR $BATL $OPEN $FRGT I am looking at $LNSR now. $12 stock on sale for $7 after buyout fell through!
0 · Reply
FiftyEight
FiftyEight Mar. 18 at 12:38 PM
$LNSR cheap entry point
0 · Reply
erevnon
erevnon Mar. 18 at 11:12 AM
BTIG upgrades LENSAR $LNSR from Neutral to Buy and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
SummerPalaceTrades
SummerPalaceTrades Mar. 17 at 10:29 PM
$LNSR Merger happening?
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Mar. 17 at 5:08 PM
$LNSR idk what kinda value remains even with the 10MM but these broken deal plays can take 6-12mo or more to bottom out
0 · Reply
notreload_ai
notreload_ai Mar. 17 at 11:31 AM
$LNSR and $ALC have mutually terminated their merger after the Federal Trade Commission threatened to block the deal. https://notreload.xyz/lensar-terminates-alcon-merger-after-ftc-block-stock-drops/
0 · Reply
BioGem
BioGem Mar. 17 at 7:14 AM
$LNSR I would short anything above $8, many lethal negatives. -Adoption and growth are weak over the years. -Gross margin is terribly low. -Operating expenses are swelling = heavy losses and are far away from any breakeven. -Cash is critically low. -Raised expensive debt = high interest with worse net losses, the spiral toward financial stress is accelerating. -Preferred shares and warrants vested are quite dilutive.
1 · Reply
DonCorleone77
DonCorleone77 Mar. 17 at 3:23 AM
$BKKT $LIDR $NUAI $MVST $LNSR AFTER-HOURS MOVERS: Currently Higher After Earnings: - Green Dot (GDOT) up 7.0% - Babcock & Wilcox Enterprises (BW) up 4.9% - Bally's Corporation (BALY) up 3.6% Currently Also Higher: - AEye, Inc. (LIDR) up 48.4% after Nvidia partnership announcement - New Era Energy & Digital (NUAI) up 8.6% after naming new CFO Currently Lower After Earnings: - Microvast Holdings (MVST) down 22.1% - Comtech Telecommunications (CMTL) down 9.9% - Consolidated Water Co. Ltd. (CWCO) down 7.5% - Bakkt (BKKT) down 6.5% - Ampco-Pittsburgh (AP) down 3.0% Currently Also Lower: - LENSAR (LNSR) down 23.5% after terminating Alcon merger - Rhythm Pharmaceuticals (RYTM) down 5.0% after announcing EMANATE trial substudies did not meet primary endpoints
0 · Reply
mikesterz7
mikesterz7 Mar. 16 at 11:07 PM
$LNSR Lensar said that its deal with Alcon is unlikely to receive necessary regulatory approvals in the U.S. by April 23 or even by July 23.
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 16 at 10:37 PM
Lensar Stock Slumps After Hours On Ending Merger Deal With Alcon Over FTC Pushback $LNSR $ALC https://stocktwits.com/news/equity/markets/lensar-stock-slumps-after-hours-on-ending-merger-deal-with-alcon-over-ftc-pushback/cZ3PQ0JRIQI
0 · Reply
HotBaht
HotBaht Mar. 16 at 9:20 PM
$LNSR Well guess that was the insider move last week. Will be ugly 6-9 months likely. But $11 Per share was under intrinsic value.
0 · Reply
GrandPoobahofBagholders
GrandPoobahofBagholders Mar. 16 at 9:03 PM
$LNSR Merger not approved, but company gets to keep the $10 million depisit.
0 · Reply